Expand ZYME Menu
ZYME MENU

ZYME Latest Press Releases

-- March 30, 2026 --

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRa-Targeting Antibody-Drug Conjugate Globe Newswire 6:00 AM

-- March 24, 2026 --

Zymeworks Announces Participation in Upcoming Investor Conferences Globe Newswire 6:00 AM

-- March 18, 2026 --

Zymeworks Announces Presentations for Ziihera (zanidatamab-hrii) at 2026 AACR Annual Meeting Globe Newswire 7:46 AM

-- March 17, 2026 --

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting Globe Newswire 5:11 PM

-- March 2, 2026 --

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing Globe Newswire 6:10 AM
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing Globe Newswire 6:01 AM
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results Globe Newswire 6:00 AM

-- February 12, 2026 --

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026 Globe Newswire 6:00 AM

-- January 27, 2026 --

Zymeworks Announces Participation in Upcoming Investor Conferences Globe Newswire 6:00 AM

-- January 12, 2026 --

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy Globe Newswire 6:00 AM

-- January 11, 2026 --

Zymeworks Outlines Strategic Priorities and Outlook for 2026 Globe Newswire 6:00 PM

-- January 6, 2026 --

Ziihera (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit Globe Newswire 1:34 PM

-- December 2, 2025 --

Zymeworks Announces Participation in Upcoming Conferences Globe Newswire 4:05 PM

-- November 18, 2025 --

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033 Globe Newswire 8:45 AM
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer Globe Newswire 1:01 AM
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets Globe Newswire 1:00 AM

-- November 17, 2025 --

Key Catalysts Emerge in Oncology, Synthetic Biology, and M&A Activity as Markets Open Globe Newswire 10:48 AM
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma Globe Newswire 6:00 AM

-- November 6, 2025 --

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results Globe Newswire 4:05 PM
Market Data Delayed 15 Minutes